Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The perforin–granzyme–Fas ligand apoptotic pathway comprises the primary cytotoxic mechanisms used by activated cytotoxic T lymphocytes (CTLs) and NKT(-like) lymphocytes to induce apoptosis of target cells. These mechanisms include the granule exocytosis pathway, in which perforin, a pore-forming protein, facilitates the entry of serine proteases called granzymes (particularly granzyme B) into target cell cytosol, thereby cleaving key substrates to activate apoptotic cascades, including direct caspase activation and mitochondrial disruption. Separately, Fas ligand (FasL) on T/NKT cells binds to Fas receptor on target cells, triggering the formation of the death-inducing signaling complex (DISC) and activation of caspases. Both routes converge on apoptotic executioner mechanisms to eliminate virus-infected, tumor, or otherwise dangerous cells. The pathway does not represent a single molecular target but rather a convergence of several effector mechanisms characteristic of cytotoxic lymphocytes.
Induction of apoptosis via: - Perforin-dependent delivery of granzymes into target cells - Fas ligand–Fas receptor interaction triggering caspase activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Perforin–granzyme–Fas ligand apoptotic pathway.